Maria Soledad Undurraga

TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).

TL;DR: The establishment of the IC-APL network resulted in a decrease of almost 50% in early mortality and an improvement in OS of almost 30% compared with historical controls, resulting in OS and DFS similar to those reported in developed countries.

TL;DR: It is concluded that FLT3-ITD mutations are associated with several hematologic features in APL, in particular with high white blood cell counts and may independently predict a shorter survival in patients with APL treated with ATRA and anthracycline-based chemotherapy.

TL;DR: Daunorubsicin and idarubicin have similar antileukaemic efficacy in terms of primary resistance, molecular persistence, as well as molecular and haematological relapse rates when combined with ATRA in treatment of APL, but a higher toxic death rate during induction and consolidation therapy was observed in the IC-APL cohort.

TL;DR: In this article, SanzGrimwade, Arnold Ganser, Nancy Berliner, Raul C. Ribeiro, Francesco Lo-Coco, Bob Lowenberg andGarces-Eisele, Robert Gallagher, Charlotte M. Schrier, Martin Tallman, DavidChiattone, Lem Martinez, Luis A. Meillon, David Gomez-Almaguer, Hau C. Kwaan, Javier Ricardo Pasquini, Katia Pagnano, Evandro M. Jacomo, Homero Gutierrez-Aguir